Myomo
Myomo's revenue rose 25.7% to $41 million in fiscal 2025. Its operating margin was −35.2%, down from −19.1% a year earlier. Free cash flow was −$16 million. The diluted share count rose 10.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Myomo lost money in fiscal 2025: a net loss of $16 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 16 | 5 | 9 | 25 | 18 |
| Debt incl. finance leases | — | — | — | 0 | 11 |
| Net debt (negative means net cash) | — | — | — | −25 | −7 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.0x | 1.0x |
| Interest coverage | — | — | — | — | −128.7x |
| Current ratio | 4.5x | 2.6x | 2.5x | 3.2x | 3.3x |
| Quick ratio | 4.3x | 2.2x | 2.2x | 2.9x | 2.9x |
Cash flow
Projections
Project Myomo's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Myomo says to expect
- Full year 2026: revenue
Narrowing full-year revenue guidance to $46-47 million, at the upper end of previous guidance
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $439,324 of Myomo shares on the open market, and 2 insiders sold $102,893.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Harry KovelmanChief Medical Officer | Sold | 15,488 | $1.27 | $19,670 | Form 4 |
| Sep 2, 2026 | Milton Mayo MorrisDirector | Sold | 15,000 | $1.41 | $21,150 | Form 4 |
| Aug 20, 2026 | Harry KovelmanChief Medical Officer | Sold | 17,250 | $1.73 | $29,842 | Form 4 |
| Jun 5, 2026 | Thomas F KirkDirector | Bought | 40,002 | $1.27 | $50,803 | Form 4 |
| May 28, 2026 | Thomas F KirkDirector | Bought | 25,000 | $0.99 | $24,750 | Form 4 |
| May 28, 2026 | Harry KovelmanChief Medical Officer | Sold | 11,536 | $1.02 | $11,767 | Form 4 |
| May 27, 2026 | Harry KovelmanChief Medical Officer | Sold | 20,464 | $1.00 | $20,464 | Form 4 |
| May 18, 2026 | Thomas F KirkDirector | Bought | 43,401 | $0.91 | $39,495 | Form 4 |
| May 15, 2026 | Thomas F KirkDirector | Bought | 31,605 | $0.91 | $28,761 | Form 4 |
| May 15, 2026 | Joseph M. Manko Jr.Director | Bought | 30,367 | $0.89 | $27,027 | Form 4 |
| May 14, 2026 | Joseph M. Manko Jr.Director | Bought | 170,830 | $0.86 | $146,914 | Form 4 |
| Mar 16, 2026 | Heather C GetzDirector | Bought | 20,000 | $0.70 | $14,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 3 of 9 |
| Rule of 40 | −9.1% | 54.9% | −14.0% |
| Altman Z'' | −20.10 | −3.95 | −8.82 |
| Accruals ratio | −16.0% | −10.2% | −2.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | 3 of 9 |
Compare
Put Myomo side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Myomo | FY25 | 25.7% | −35.2% | −39.7% | — | — | 3 | |
| KORU Medical Systems | FY25 | 22.2% | −7.2% | −1.1% | — | — | — | Compare |
| Pulsenmore | FY25 | 314.3% | — | −82.5% | — | — | — | Compare |
| SS Innovations International | FY25 | 105.7% | −19.3% | −52.3% | — | — | — | Compare |
| Utah Medical Products | FY25 | −5.8% | 29.6% | 37.2% | 26.8% | −6.0x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 2 | 2 | 4 | 8 | 14 | 16 | 19 | 33 | 41 |
| Revenue growth | — | 41.3% | 56.8% | 57.0% | 97.6% | 82.7% | 12.3% | 23.7% | 69.2% | 25.7% |
| Gross profit | 1 | 1 | 2 | 2 | 5 | 10 | 10 | 13 | 23 | 27 |
| Research and development | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 5 | 7 |
| Operating income | −3 | −6 | −10 | −11 | −10 | −10 | −11 | −8 | −6 | −14 |
| Net income | −4 | −12 | −10 | −11 | −12 | −10 | −11 | −8 | −6 | −16 |
| Diluted EPS (US$) | −123.90 | −87.90 | −25.18 | −20.79 | −3.67 | −1.89 | −1.52 | −0.28 | −0.16 | −0.37 |
| Diluted shares (millions) | 0 | 0 | 0 | 1 | 3 | 6 | 7 | 30 | 38 | 42 |
| Cash flow | ||||||||||
| Cash from operations | −3 | −6 | −10 | −10 | −9 | −10 | −10 | −6 | −3 | −14 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Free cash flow | −3 | −6 | −10 | −10 | −9 | −10 | −10 | −6 | −5 | −16 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 1 | 13 | 6 | 4 | 12 | 16 | 5 | 9 | 25 | 18 |
| Debt incl. finance leases | 2 | — | — | 3 | — | — | — | — | 0 | 11 |
| Total assets | 2 | 14 | 8 | 7 | 15 | 20 | 10 | 15 | 42 | 39 |
| Total liabilities | 6 | 2 | 2 | 5 | 3 | 5 | 4 | 6 | 18 | 27 |
| Shareholders' equity | −18 | 12 | 6 | 6 | 12 | 15 | 6 | 9 | 25 | 11 |
| Margins and ratios | ||||||||||
| Gross margin | 74.4% | 67.6% | 70.2% | 63.0% | 65.7% | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| Operating margin | −296.8% | −420.1% | −430.8% | −281.3% | −138.5% | −74.1% | −68.6% | −42.8% | −19.1% | −35.2% |
| Net margin | −327.8% | −776.0% | −422.1% | −279.1% | −152.5% | −74.9% | −68.9% | −42.3% | −19.0% | −38.0% |
| Free cash flow margin | −290.5% | −399.0% | −398.2% | −270.8% | −119.7% | −71.3% | −66.5% | −32.8% | −14.3% | −39.7% |
| Rule of 40 (growth + FCF margin) | — | −357.7% | −341.4% | −213.8% | −22.1% | 11.5% | −54.2% | −9.1% | 54.9% | −14.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −109.3% | −166.7% | −128.6% | −76.9% | −98.5% | −106.2% | −36.7% | −86.2% |
| Return on assets | — | −154.8% | −92.7% | −144.0% | −108.5% | −59.6% | −70.9% | −65.9% | −21.8% | −38.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |